Learn
Looking for more information?
Contact our responsive and friendly client services team any time.
Current price
$0.0165
▾0.001 (3.13%)
Last trade: 28/11, 2:02AM
Market cap
$21.21m
20 min delay
Investor Presentations
Principal Activity
Living Cell Technologies (LCT) develops cell therapies to treat diseases with high unmet clinical needs. The Australasian biotechnology company is a global pioneer in the field of cell encapsulation and implantation for human therapeutics. To date, the company has taken two therapeutic candidates into clinical development: DIABECELL for the treatment of type 1 diabetes and NTCELL , which is in Phase I clinical trials in New Zealand for the treatment of Parkinson's disease. Former Names --
Address
Level 7/330 Collins St, Melbourne VIC 3000, Australia
Website
News
Announcements
Filter
| Announcement | T+2 Movement | Date |
|---|---|---|
Market Data
Day
3m
1yr
5yr
Current price
$0.0165
Open price
-
Day low-high
-
Price change
Percent change
Previous close
-
Volume
-
Turnover
-
Bid price
-
Ask price
-
Market cap
-
Shares outstanding
-
Year high
-
Year low
-
Year low-high
-
Earnings per share
-
Price/earnings ratio
-
Dividend yield
-
Dividend per share
-
Franking
-
Investor Presentations
News
Sector Peers
| Company | Market Cap | ||
|---|---|---|---|
Support
Live Chat
Markets
Contact Us
(03) 9661 0441
clients@freshequities.com
Address
Level 16, 452 Flinders St
Melbourne VIC 3000
Australia